Mediation analysis showed that specific gut microbiota influenced ITP development through cytokine pathways. A recent investigation has provided important insights into the role of gut microbiota and ...

Acute neuritis due to anti-myelin oligodendrocyte glycoprotein associated disease (MOGAD) improves without acute treatments, while myelitis due to MOGAD improves less if not treated, according to a ...

The management of neonatal neutropenia mostly encompasses close monitoring and supportive care. Neutropenia in neonates with hemolytic disease of the fetus and newborn (HDFN) is predominantly benign ...

In patients with SCD, although the lifespan of their reticulocytes remains unknown, the number of immature reticulocytes is on the rise. Research has shown that reticulocytosis can predict morbidity ...

Which of the following statements about the pathophysiology of systemic mastocytosis (SM) are correct? Select one of the options for each question, then submit your answers to see how well you scored ...

VEXAS syndrome can often mimic AAV presentation, complicating diagnosis. An elderly man diagnosed with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome was initially ...

Rituximab was highlighted by the study's authors as an attractive alternative for patients who are intolerant to steroids or prone to IgG4-RD relapses. A new systematic review and meta-analysis has ...

In terms of the safety profile, 40 patients (37%) experienced injection site reactions as the most frequent adverse event. Real-world data confirms the safety profile of IgPro20 for patients with ...

Clonal dynamics varied across patients with advanced SM, with some subclones persisting despite treatment. Subclonal architecture analysis showed varying clonal dynamics, with some subclones ...

The safety profile of WVE-006 has been favorable, with all reported adverse events being mild to moderate. No serious adverse events have been observed. WVE-006, an RNA editing therapy aimed at ...

Clinicians may wish to consider emerging treatments such as avapritinib, a mast cell-depletion agent, for highly symptomatic cases of SM. A female patient with indolent systemic mastocytosis (ISM), a ...

In the Japanese open-label extension study, patients with CAD reported fewer treatment-emergent adverse events. One patient experienced mild urinary tract infection linked to sutimlimab. Sutimlimab ...